相关实验视频
Updated: Jul 16, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
针对突变p53进行癌症治疗:我们还在吗?
Dhi Vya Lim1, Wei Hwei Woo1, Jing Xuan Lim1
1School of Pharmacy, Faculty of Health & Medical Sciences, Taylor's University, 1, Jalan Taylors, 47500, Subang Jaya, Selangor, Malaysia.
突变的p53蛋白质驱动癌症生长和治疗耐药性. 针对这些突变p53蛋白的新抑制剂正在出现,APR-246在临床试验中显示出显著的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 人类癌症中TP53基因的突变很常见,导致突变p53 (mutp53) 蛋白质的形成.
- Mutp53促进癌细胞的增殖,迁移,入侵和转移.
- Mutp53有助于瘤发生,并赋予化学疗法和放射治疗的耐药性.
研究的目的:
- 审查突变p53在癌细胞瘤发生中的作用.
- 讨论当前突变p53抑制剂在临床前和临床开发中的情况.
- 提供关于这些抑制剂的临床进展的最新信息.
主要方法:
- 关于突变p53瘤发生的研究的文献综述.
- 对突变p53抑制剂的临床前和临床数据的分析.
- 突出化合物可以恢复野生类型的p53形状或DNA结合.
主要成果:
- 突变的p53积极推动癌症的开始和进展.
- 一些突变的p53抑制剂正在研究中,它们的作用机制各不相同.
- APR-246已进入第三阶段临床试验,表明其具有显著的治疗潜力.
结论:
- 向突变p53代表了癌症治疗开发的一个有希望的途径.
- 突变p53抑制剂可以抵消癌细胞生存,迁移和转移.
- APR-246是开发突变p53向疗法的领先候选者.
更多相关视频
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
相关概念视频
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
DNA Damage can Stall the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...